Equities

Roquefort Therapeutics PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Roquefort Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.10
  • Today's Change-0.10 / -8.33%
  • Shares traded258.92k
  • 1 Year change-57.69%
  • Beta0.0565
Data delayed at least 20 minutes, as of Feb 09 2026 14:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Roquefort Therapeutics PLC is a United Kingdom-based material biotech company. The Company is engaged in preclinical development of next generation medicines focused on hard-to treat cancers. The Company’s portfolio consists of over five novel patent-protected pre-clinical anti-cancer medicines. Its portfolio of medicines include Midkine antibodies with in vivo efficacy and toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics targeting solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significant in vivo efficacy, and MK cell therapy with direct and Natural Killer cell-mediated anti-cancer action. The Company has partnered with leading academic cancer research centers which complement its own in-house expertise and laboratory infrastructure.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-882.45k
  • Incorporated2020
  • Employees1.00
  • Location
    Roquefort Therapeutics PLC85 Great Portland Street,, First FloorLONDON W1W 7LTUnited KingdomGBR
  • Phone+44 203 918 8633
  • Websitehttps://www.roquefortplc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shortwave Life Sciences PLC45.70k-256.99k868.17k2.00--0.2391--19.00-0.007-0.0070.00120.06690.0155--2.2622,850.00-8.73---9.00--99.34---562.34------0.00---19.39--76.00------
Roquefort Therapeutics PLC0.00-882.45k1.96m1.00--0.3975-----0.0063-0.00630.000.03020.00----0.00-15.04---17.23-------------17.400.0747---100.00--44.29------
ValiRx Plc49.78k-1.78m2.56m14.00--0.3742--51.48-0.0094-0.00940.00020.00920.01470.000.60683,555.71-55.35-48.98-51.45-49.62100.00---3,775.95-16,086.598.87--0.0022--418.54--5.99---37.39--
N4 Pharma PLC7.07k-1.07m3.95m4.00--2.24--559.17-0.0025-0.00250.000020.00210.0045--0.07561,767.50-71.04-59.59-74.91-63.90-----15,981.33-67,987.22----0.00--273.33--16.60------
TheraCryf PLC0.00-2.01m4.51m9.00--0.9398-----0.0017-0.00170.000.00220.00----0.00-41.20-38.70-53.79-42.97-------1,407.46----0.00---100.00--38.13------
Ovoca Bio PLC0.0065.12k5.28m1.00--2.2181.08---0.0064-0.01590.000.03730.00----0.003.15-30.403.64-33.15------------0.00------99.94------
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.00---------0.0028-0.00280.00-0.00070.00-------190.34-146.14-433.59-169.40--------0.4766-2.42---------26.15------
Futura Medical PLC7.93m-6.29m7.41m12.00--1.27--0.9351-0.0207-0.02070.02610.011.06137.368.58---84.19-45.00-112.42-71.7970.67---79.41-108.252.21--0.00--349.09237.55119.85--121.02--
OptiBiotix Health PLC1.15m-191.00k7.90m5.00--0.9385564.466.87-0.0018-0.00180.01130.08150.1341.932.88230,200.00-2.2217.23-2.3317.8445.4450.78-16.59189.343.75--0.0094.9335.093.1511.48------
IXICO PLC6.53m-1.65m9.50m79.00--0.8093--1.45-0.0186-0.01860.0730.12670.5222--3.1882,708.86-13.19-3.47-15.43-4.0348.7155.52-25.27-6.21----0.015--13.32-7.2717.49---5.30--
Data as of Feb 09 2026. Currency figures normalised to Roquefort Therapeutics PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.